Development of heparin fractions: some overlooked considerations.
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism / Q000494:pharmacology; D001682:Biological Availability; D001711:Biotransformation; D001780:Blood Coagulation Tests; D055598:Chemical Phenomena; D002621:Chemistry; D004195:Disease Models, Animal; D004341:Drug Evaluation; D004355:Drug Stability; D005170:Factor X / Q000037:antagonists & inhibitors; D015951:Factor Xa; D005342:Fibrinolysis / Q000187:drug effects; D005344:Fibrinopeptide A / Q000378:metabolism; D006470:Hemorrhage / Q000139:chemically induced; D006493:Heparin / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007700:Kinetics; D011516:Prothrombin / Q000037:antagonists & inhibitors; D011655:Pulmonary Embolism / Q000188:drug therapy; D013329:Structure-Activity Relationship; D013924:Thrombophlebitis / Q000188:drug therapy
D005344:Fibrinopeptide A; D000990:Antithrombin III; D011516:Prothrombin; D005170:Factor X; C025337:Factor IIa; D006493:Heparin; D015951:Factor Xa